LENZ Therapeutics, Inc.
LENZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815776
No open-market purchases or sales by LENZ Therapeutics, Inc. insiders were filed in the last 90 days; 145 institutions reported holding it in 13F filings for Q2 2026, worth $197.3M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding LENZ Therapeutics, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 114 | 166 | +52 |
| Shares | 24.7M | 29.1M | +4.41M (+17.8%) |
| Value | $725.1M | $1.36B | +$630.5M (+86.9%) |
New holders (57)
Institutions that held LENZ Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (5)
Institutions that held LENZ Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Sectoral Asset Management Inc | 977,245 | $28.6M |
| StemPoint Capital LP | 183,912 | $5.39M |
| American Century Companies Inc | 30,109 | $882.5K |
| IFP Advisors, Inc | 0 | $176 |
| Stephens Consulting, LLC | 1 | $30 |